Depression Research Unit, University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania, 19104-3309, United States
NCT Number: NCT00120458
This study will determine the effectiveness of the herb black cohosh for treating menopause-related anxiety symptoms in women.
Study hypotheses: 1) Black cohosh will have a superior anti-anxiety effect compared to placebo. 2) Black cohosh will have a comparable safety profile to that of placebo.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Phase 4
Philadelphia, Pennsylvania, 19104-3309, United States
During menopause, up to 90% of women will experience symptoms of anxiety, such as nervousness, irritability, fatigue, muscle aches, depression, and low libido. Concern over the safety and effectiveness of hormone replacement therapy for relieving these symptoms has caused many women to seek alternative medical treatments. Data suggest that black cohosh has a direct effect on the neurotransmitters and receptors involved in anxiety. This study will determine whether black cohosh can effectively treat anxiety symptoms in menopausal women.
This study will last 12 weeks. Participants will be randomly assigned to receive either black cohosh or placebo daily for the duration of the study. Self-report scales will be used to assess participants' anxiety symptoms and quality of life at the beginning and end of the study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
32 to 128 mg (black cohosh)
1 to 4 capsules daily (placebo)
Time frame: 12 Weeks
Time frame: 12 Weeks
University of Pennsylvania
Other
Black Cohosh Therapy for Menopause-Related Anxiety
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05503017
Anxiety Disorders, Generalized Anxiety Disorder
Tallahassee, Florida, United States
View Trial DetailsNCT03585010
Anxiety Disorder of Childhood, Anxiety Disorders
New Haven, Connecticut, United States
View Trial DetailsNCT07452835
Anxiety Disorders, Depressive Disorder
Cairo, Menofia, Egypt
View Trial DetailsNCT06046170
Anxiety, Anxiety Disorders
Baltimore, Maryland, United States
View Trial Details